Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-25 @ 8:53 PM
Study NCT ID:
NCT01744756
Status:
COMPLETED
Last Update Posted:
2012-12-07
First Post:
2012-11-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Subconjunctival Bevacizumab and Recurrent Pterygium
Sponsor:
Instituto de Olhos de Goiania
Organization:
Study Overview
Official Title:
Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRP
Brief Summary:
A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.
Detailed Description:
1. Pacients with recurrent pterygium
2. Anti-VEGF therapy -Bevacizumab
2. Anti-VEGF therapy -Bevacizumab
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: